Potential conflict of interest: Dr. Yazdanpanah consults for Abbott, Bristol-Myers Squibb, Gilead, Tibotec, ViiV Healthcare, and MSD.
Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: A modeling approach
Article first published online: 25 FEB 2014
© 2014 by the American Association for the Study of Liver Diseases
Volume 59, Issue 4, pages 1471–1481, April 2014
How to Cite
Mourad, A., Deuffic-Burban, S., Ganne-Carrié, N., Renaut-Vantroys, T., Rosa, I., Bouvier, A.-M., Launoy, G., Cattan, S., Louvet, A., Dharancy, S., Trinchet, J.-C., Yazdanpanah, Y. and Mathurin, P. (2014), Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: A modeling approach. Hepatology, 59: 1471–1481. doi: 10.1002/hep.26944
Supported by a grant (INCa_1496) from the French National Cancer Institute (INCa), the Cancer Research Association (ARC) and the French National AIDS and Viral Hepatitis Research Agency (ANRS) teamed up to launch an Integrated Research Action Programme on hepatocellular carcinoma (HCC PAIR).
- Issue published online: 24 MAR 2014
- Article first published online: 25 FEB 2014
- Accepted manuscript online: 21 NOV 2013 02:20AM EST
- Manuscript Accepted: 18 NOV 2013
- Manuscript Received: 9 JUN 2013
Because of the ongoing debate on the benefit of ultrasound (US) screening for hepatocellular carcinoma (HCC), we assessed the impact of screening on hepatitis C virus (HCV)-related compensated cirrhosis patients aware of their HCV status. A Markov model simulated progression from HCC diagnosis to death in 700 patients with HCV-related compensated cirrhosis aware of their HCV status to estimate life expectancy (LE) and cumulative death at 5 years. Five scenarios were compared: S1, no screening; S2, screening by currently existing practices (57% access and effectiveness leading to the diagnosis of 42% at Barcelona Clinic Liver Cancer stage [BCLC-0/A]); S3, S2 with increased access (97%); S4, S2 with an efficacy of screening close to that achieved in a randomized controlled trial leading to the diagnosis of 87% of patients at stage BCLC-0/A; S5, S3+S4. The analysis was corrected for lead-time bias. Currently existing practices of HCC screening increased LE by 11 months and reduced HCC mortality at 5 years by 6% compared to no screening (P = 0.0013). Compared to current screening practices, we found that: 1) increasing the rate of access to screening would increase LE by 7 months and reduce HCC mortality at 5 years by 5% (P = 0.045); 2) optimal screening would increase LE by 14 months and reduce HCC mortality at 5 years by 9% (P = 0.0002); 3) the combination of an increased rate of access and optimal effectiveness of HCC screening would increase LE by 31 months and decrease HCC mortality at 5 years by 20% (P < 0.0001). Conclusion: The present study shows that US screening for HCC in patients with compensated HCV-related cirrhosis aware of their HCV status improves survival and emphasizes the crucial role of screening effectiveness. (Hepatology 2014;59:1471-1481)